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ABSTRAcr 
The results of our personal studies of alpha-I-protease inhibitor 
(APi, forrrerly terned alpha-I-antitrypsin), the major inhibitor of 
protease in extracellular fluids, are presented in this dissertation. 
In the first chapter, we describe techniques used for APi quanti-
tation and determination of Pi phenotypes. After a brief review of the 
available tedhniques, we report several ~rovements on our original 
technique of Pi phenotyping using thin-layer isoelectric focusing. 
Particular attention is given to biodherndcal and Lrnmunological methods 
for verification of the results obtained t¥ isoelectric fOQlsing. Three 
corrplenentary techniques are reported: protease prote, crossed imnuno-
electrophoresis, and print ~ofixation. Analysis of the results from 
print Lmmunofixation, using ~crodensitomet~, is of special interest. 
In the seoond chapter, the alleles and phenotypes of the pi system 
are described. We report a detailed study of the distribution of Pi 
phenotypes in two different populations and corrpare our results with 
those previously reported in the literature, including more than 30,000 
subjects. We also correlate serum APi levels with the various pheno-
types. Our results derronstrate the existence of three new allele 
products -- Me, Mb, and 12- In addition, we report that serum levels of 
APi are slightly elevated in subjects with the Mb or Me allele, whereas 
a marked reduction is associated with the e~ression of the I allele. 
An additional study oonCErning Pi phenotype determination in oord blood 
is presented, and the origin of the pattern of APi in newborns is 
disoossed. The ~ortance of APi as a genetic rrarker is enphasized. 
The third Chapter deals with the structure and biological role of 
APi. After a sumrrary of the Olrrent knONledge on APi structure, we 
report an original investigation concerning desialylation of APi. ~be 
results suggest that sialic acids do not account for the rracrohetero-
geneity and polymorphism of APi. A study of the binding of elastase and 
trypsin with APi shCMS that, in excess of APi, a stable corrplex is 
formed. In contrast, in excess of proteases the complex is dissociated, 
with release of altered APi and of the protease previously inactivated. 
In the fourth chapter, the clinical consequences of APi deficiency 
are examined. The role of APi deficiency in pulrronary and liver dis-
eases is reviewed, and evidence for its predisposing role in nonatopic 
asthma of infancy, herrochronatosis, juvenile chronic polyarthritis, and 
squamous cell carcinoma is presented. 
INTRODUCTION 
'lnis dissertation is a compendium of studies, experience, and ideas 
concerning the major protease inhibitor of extracellular fluids, 
Alpha-I-Proteinase inhibitor (APi), the clinical interest of which 
started with the study of deficient Pi phenotypes associated with 
pulmonary diseases. This work presents the newest findings in 
methodologic, genetic, biochemical and clinical studies, which 
supplement an initial report presented in 1975 (1) c· 
The dissertation is divided in four parts, grouping the major 
research areas by subject for greater clarity of presentation. The 
first area deals with both macroheterogeneity and polymorphism as 
defined py acid starch gel electrophoresis, an early method to study 
these characteristics first reI,X>rted by Fagerhol (2). In 1974, Arnaud 
et al. (3) reported that an identical microheterogeneity and 
polymorphism was found when serum was sublldtted to isoelectric focusing 
in a gradient of pH 4-6 (3), and Allen et ala (4) on a pH gradient 
3.5-5. T'hese findings were soon confirmed by other investigators (5) in 
1974. 1herefore, the first section is devoted to this area, and its 
major emphasis is on new adjuncts to the technique of isoelectric 
focusing which permit direct verification by three separate confirmatory 
techniques for APi allele products. These include tests for 
denaturation, ability to bind trypsin (6), and immunological methods, 
particularly the print tmmunofixation technique developed specifically 
for such studies (7)0 
The second section deals with the genetics of the proteinase 
inhibitor system, which in each individual is thought to be under the 
control of two autosomal codominant alleles. . ~Dre than 25 different 
alleles have been reported and more than 45 resulting phenotypes have 
been clearly defined (1), although more than 325 combinations are 
theoretically possible. A review is made of all world reports on Pi 
types, and the results for distributions of types are compared with 
those of two studies carried out as part of this research, one utilizing 
serum from a French population and the other from Charleston, presumably 
a more heterogenous population, comprising over 3000 people. In 
addition r two new all~les which are variants of the common M allele are 
described. These alleles have been designated respectively Mb and Me. 
The relationship beteween phenotypes and serum APi values is:(eported in 
588 healthy subjects, and two conclusions are drawn: the M variants Mb 
. and Me are associated with APi levels slightly higher than the ones 
associated ~ith MM phenotypes, and conversely, the I allele is 
associated with decreased serum levels. The importance of APi as a 
genetic marker is ewphasized. Preliminary population studies in cord 
blood indicate that an accurate pi type can be interpreted from fresh 
cord blood. In addition, the origin of slight variations in newborn 
serum Pi patterns is discussed. 
The third section includes studies on the structure and function of 
the alpha-I-proteinase inhibitor, with special attention to the amino 
acid and sugar composition of M and variant proteins. A new technique 
for isolation and purification of APi is described. The role of the 
sialic acids in ruacroheterogeneity and polymorphism of APi is discussed 
on the basis of extensive studies of desialylation of MM, SS, and ZZ 
variants from normal serum. Additional data concerning the binding of 
trypsin and elastase to APi are reported. These indicate that, in 
excess of proteolytic enzymes, the complex between APi and enzymes is 
dissociated, leading to a denatured form of APi unable to exert a 
protease binding role and the consequent release of the protease 
previously inactivated. 
In the last part, the clinical disorders associated with APi 
deficien~ are presented. Special attention is given to connective 
tissue diseases, in which the role of APi deficiency appears to play an 
increasingly ~rtant role. In this section, studies demonstrating a 
high frequency of deficient pi phenotypes in nonatopic asthma of infants 
are described, and a significant increase of the Z allele in juvenile 
chronic polyarthritis and in squamous cell lung cancer is indicated. A 
preliminary study also indicates that the presence of a deficient allele 
is a predisposing factor in the onset of periodontal disease, and 
conversely, that the M variant Me protects against its occurrence (8). 
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HISroRICAL BACKGROUND 
The first observations of antitryptic activity of serum were 
reported in 1894 by Fermd and Pernossi (9) and in 1897 by Camus and Gley 
(10). In 1900, Landsteiner noted that this activity was mainly 
associated with the albumin fraction (11). A detailed study of 
leukoproteases and antileukoproteases of mammals and birds was presented 
in 1907 by Opie and Barker in one of the first issues of the Journal of 
Experimental Medicine (12). 
Following this descriptive step, the next stage mainly involved the 
isolation and purification of the protein(s) responsible for this 
activity. The first attempt was reported by Schmitz in 1968 (13). 
Following the observation of Shulmann (14) demonstrating that, in fact .. 
two distinct inhibitors of protease were present in serum, Jacobsson 
(15,16) separated them and further demonstrated that 90% was present in 
the alpha-l globulin zone and 10% in the alpha-2 zone. Bundy and Mehl 
(17) in 1959 reported partial characterization. In fact, in 1955, 
Schultze already had isolated an alpha-l 3-5 glycoprotein from the 
alpha-l globulin fraction and reported some physicocherodcal properties 
without relating this fraction to proteins responsible for the 
antiproteolytic activity of serum (18). Seven years later, he 
established the identity between the major protease inhibitor of serum 
and the alpha-l 3-5 glycoprotein and, with regard to its biological 
properties, gave it the name "alpha-I-antitrypsin" (19). 
In 1962, Laurel1 observed that sera of some patients when separated 
by electrophoresis lacked the alpha-l band. These serum samples came 
from a sanatorium, and case histories revealed that these subjects had 
chronic obstructive lung diseases (20). In his dissertation thesis, 
Eriksson in 1965 (21) reported the detailed clinical histo~ of patients 
associating pulmonary emphysema and alpha-l-antitrypsin deficiency. The 
same year, Fagerho1 and Braend (22), studying serum proteins with 
discontinuous acid starch gel electrophoresis, discovered a ge~etically 
deterfidned polymorphic system present in the prealbumin zone. TWo years 
later, Fagerhol and Laurell (23) demonstrated that this system 
corresponded to the mrrcroheterogeneity and polymorphism of 
alpha-I-antitrypsin. They also demonstrated that the deficient state 
was associated with the expression of a slow migration phenotype called 
IIZZ", and proposed for this protein system the term "protease inhibitor t1 
or "pi" (24). 
In 1969, Sharp (25) reported the first case of the association of 
APi deficien~ type ZZ and neonatal cirrhosis. He further demonstrated 
(26) the accumulation in the liver of these patients of a material 
immunologically related to APi. Lieberman (27) reported identical 
findings in zz patients and in heterozygous NZ patients with pulmonary 
diseases. In 1973, Talamo (28) reported the case of a patient with 
total serlUU deficiency, providing the existence of a "null" (-) allele 
for the expression of APi. 
According to the suggestion of Travis (29) that alpha-I-antitrypsin 
is not an adequate name for this protein due to its major biological 
role as an inhibitor of elastase and collagenase, the majority of the 
authors working in this field agree to substitute a new designation 
"alpha-I-protease inhibitor" (APi). 
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Chapter 1 
APi QUAL~TITATIQ\J AL~ pi PHENOTY.PE DETERIlINATION; TECHNICAL PARAt-1ErERS 
The first techniques used to detect APi deficiency were only 
quantitative, and based either on ~unological (30,31) or biological 
(32) quantitation. They could define only three levels of serum APi: 
normal, homozygous deficient, and intermediary (33). The discovery of 
the pi system t in which several alleles and phenotypes proved to be 
associated with serum APi deficiency, and the ability to characterize 
their expression with accuracy using acid-starch gel (34) and later 
isoelectric focusing (35,36), clearly improved the biochemical diagnosis 
of deficient types, especially in the heterozygous state. At present, 
APi level determinations are only a complernent of Pi typing I but they 
retain an ~rtant role and should be done in parallel with the latter. 
Each technique provides important information, and their combined 
results are necessary for an accurate determination of the APi status. 
I. APi Measurement 
A. Immunological techniques; These nethods are employed to 
quantify APi levels in biological fluids by measuring the formation of 
an antigen-antibody complex between APi and a specific antiserum raised 
against pure APi. ·S.uch antibodies are ordinarily raised against APi 
isolated from sera obtained from a pool of blood donors. The 
quantitation of the precipitate formed is accomplished by three 
techniques: 
1) Radial ~unodiffusion (RID). The fluid containing APi is 
deposited in a hole made in agarose gel containing antibodies. 
Diffusion of the serum produces a precipitate with the antibody, the 
diameter of which is proportional to the amount of antigen deposited in 
the hole. 
2) Rocket electrophoresis. In this technique the antigen is drawn 
into the gel py an electric force. As the antigen migrates, a 
precipitate forms as a peak, and its height is proportional to the 
amount of antigen present. The comparison between RID and rocket 
techniques for the determination of APi levels in serum has been studied 
in detail (37), and has shown that the Laurell-rocket techniques have 
greater accuracy at lower cost. However, it needs an experienced 
technician and necessitates the use of specialized electrophoretic 
equipment. Recently, it has been proposed to used ~unonephelrnnetric 
detection of APi in biological fluidsi this method should provide 
equally good results (38). 
The above techniques are based on the specificity of the anti-APi 
antiserum. Commercially available antisera are normally of a quality 
sufficient for this purpose. More precise techniques (immuno-
B 
fluorescence), for which monospecificity of the antiserum is critical, 
require further absorption of the antiserum. Such a result can be 
obtained by absorbing a commercial antiserum on a Sepharose column on 
which a pi null human serum has been attached (39). It must be pointed 
out that comrrercially available antisera detect the M phenotype as well 
as the other molecular forms, strongly suggesting an identity of the 
major antigenic determinants present in both M and other allele 
products. Attempts to produce a specific antiserum against the Z 
variant have been unsucessful to date (4~), although Lieberman has 
reported that Z phenotypes give, in immunodiffusion, a double ring 
pattern specific for the phenotype (41). In fact, however, this 
phenomenon seems to have been due to a particular batch of antiserum and 
has not yet been reproduced. 
B.. Biological techniques. These rrethods are based upon the fact 
that APi represents over 90% of the antiprotease activity, including 
antit~tic activity, of serum (42). Therefore, the measurement of 
serum trypsin inhibito~ capacity will allow the indirect measurement of 
the APi. content of the serum. Several techniques have been reported, 
using different substrates, either natural (gelatin, aiburrrrn) or 
synthetic (benzoyl-arginine-ethyl ester, tosyl-arginine-methyl ester, 
benzoyl-arginine-naphthylamide, benz6yl-arginine-p-nitroanilide) 
(43,44). A very s~le technique, using the gelatin of photographic 
emulsion, was reported by Fudenberg approximately 10 years ago and is 
ve~ convenient for population screening due to its rapidity and low 
cost (45). A more specific measurement of the inhibitory capacity of 
serum related to its major biological role utilizes elastase as 
proteolytic enzyme (46). 
The major criticism that can be made of biological techniques is 
their partial lack of specificity. Indeed, 90% of the inhibitory 
capacity of serum is due to APi, but other inhibitory proteins, such as 
alpha-2 macroglobulin, can -also be increased (42) and this increase can 
mask a partial deficiency of APi. Due to the important overlap between 
the different levels of different phenotypes, such a technical 
imprecision could further confuse interpretation of results. 
Nevertheless, biological techniques present a major advantage for they 
measure a biological effect of APi and not antigenic sites. The trypsin 
inhibito~ capacity of serum can be decreased without modification of 
APi concentration which is estimated qy ~unological techniques in 
order to detect possible denaturation of the inhibitor (47). 
II. pi Typing Techniques 
A. Acid starch gel. In 1955, Smithies (48) introduced a new 
support for zonal electrophoresis (molecular sieve) consisting of starch 
gel. The separating performance of this support is based on the shape, 
size and charge of the molecules. In 1959, Paulik (49) adapted the 
starch gel technique to the study of the serum proteins using a 
discontinuous buffer system. Modified by Fagerhol (50), this system 
proved to separate a series of "prealbumin" bands, later identified as 
APi (51). This technique employs an acidic gel, an acidic anodal 
buffer, and a basic cathodal buffer (34,52) •. During rrdgration, the 
basic buffer progresses to the anode and gives in the gel, a rise in pH 
due to a moving boundary consecutive to the Kohlrausch effect, which is 
detected by ti1e formation of a migration front. The alkaline wave 
during its progression is progressively buffered by the acidic radicals 
of the gel buffer. A pH gradient is then progressively formed, as 
indicated b¥ pH measurements on the surface of the acid-starch gels 
(53). The separation principle in the technique of Fagerhol was in 
actuality a type of isoelectric focusing, which explains the identical 
distribution of the pi variants in both systems (35,54). 
Although a basic reference technique during the past 6 years, 
acid-starch gel presented various disadvantages: in addition to the 
difficulty inherent in this technique, several points are very critical 
and must be carefully checked, including the pH of the buffers, which 
must be controlled before every run, the efficiency of cooling, and the 
quality of starch. The best results were obtained, after assays of 
several batches of starch, using Norwegian starch (gift of M.K. 
Fagerhol) hydrolyzed in our laboratory. Moreover, the protein staining 
was weak and minor components (like those of deficient phenotypes) could 
not be readily seen on the-gel stain and had to be revealed by crossed 
~unoelectrophoresis6 All these reasons could explain why this 
technique has been used in no more than 15 laboratories in the world 
with accurate results (55). 
B. Isoelectric focusing: In 1973, Crawford (56) reported a new 
technique for isolation of APi. This author noted that "puren APi which 
he isolated was microheterogeneous when examined by isoelectric 
focusing. we then studied the pattern of other Pi types using 
thin-layer isoelectric focusing, and our first results were presented in 
January 1974 (35). More cowplete data were presented in Brugge 
(Belgium) in Pay of the same year (57) r including development of crossed 
~unoelectrophoresi~ from isoelectric focusing gels. The isoelectric 
focusing technique presents several advantages over acid-starch gel 
technique, including rapidity of migration, the capacity to study 
several samples (up to 75) s~ultaneously on the same run, a greater 
resolution, and a better reproducibility. As an example, the Z bands, 
often difficult to ascertain on direct staining of acid-starch gel, 
cannot be missed, except by inadvertance, by an experienced investigator 
on isoelectric focusing. All the phenotypes reported up to now using 
acid-starch gel electrophoresis can be identified with this technique. 
In addition, other allele products not separated on acid-starch gel 
electrophoresis have been demonstrated by isoelectric focusing. They 
include I2, ~fu, and Me (see Chapter 2). The technical requirements of 
IEF, including the recent modifications that enabled us to describe 
these new alleles, are shown in Table 1. A slightly different technique 
using gels 1.3 rnm thick containing no sucrose is shown in the same 
table. The staining and destaining steps are identical to those 
reported previously (57). Identical results were soon obtained by other 
investigators using similar or slightly modified isoelectric focusing 
techniques (36,58,59(61). 
Special attention must be given to the following points: The 
purity of acrylw~ide is critical and better results are obtained using 
recrystallized acrylamide (60). The polymerizing agent(s) are also 
important. As modified from our previous techniques, we no longer use 
T~~D, and we have decreased ammonium persulfate concentrations to only 
8 rng/gel. we did not find any advantage to modified cathode solutions 
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Table 1 
Composition of thin-layer polyacrylamide gels 
containing ampholines and rnagration conditions 
A. Thick gel (2 rom) 
Acrylamide = 2.91 9 
N N' Methylenebisacrylamide = 0.09 g 
Sucrose ~ 7.4 9 
Double distilled deionized water = 56 ml 
Ampholines: 3.5 - 5: 0.5 ml 
4.0 - 6: 2.5 m! 
Arruuonium persulfate 1%: 1 m1 
T = 5%; C = 3%; pH range = 3.5 - 5.5 
B. Thin gel (1 mm) 
Acrylamide = 2.22 9 
N N' Methylenebisacrylarnide = 0.162 9 
Double distilled deionized water = 18 ml 
Ampholines: 3.5 - 5 = 2.0 ml 
"N N N' N' Tetramethylethylenediarnine = 50 ul 
Arruuonium persulfate 0.07% = 20 ml 
T = 6%; C = 6.8%; pH range = 3.5 - 5 
c. Electrode solutions 
For thick gel: Cathode: NaOH 1.0 Poi 
Anode: H3P04 1.0 M 
For thin gel: Cathode: Ampholine 5.8, 0.4% 
Anode: H3P04 1." M 
D. Migration conditions 
For thick gel: 35 watts for 3 hr 
For thin gel: 20 watts for 30 min 
25 watts for 25 min 
30 watts for 10 rrdn 
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using glycine or T~}£D {61}. The use of a power supply permitting the 
delivery of constant power is, in our hands, the factor that most 
improved the technique, permitting a much more regular rndgration without 
any overheating. An efficient cooling system permits increased duration 
of the migration, and therefore the gel is refrigerated by a 
Lauaa-Brinkmann cooling syste~ that delivers a circulating water at a 
temperature of 0oC. The temperature of the gel is +SoC. The use of 
other stains (Coornassie G 250) did not improve in our hands the 
differentiation of the bands. When larger pH ranges are necessary, we 
use a thin gel (1.2-1.5 mm thick), the composition of which is indicated 
in Table 2. A typical isoe1ectrofocusing run in a gradient of pH 4-6 is 
indicated in Figure 1. 
c. Complementary techniques applied to isoelectric focusing: 
1) Antigen-antibody crosssed immunoelectrophoresis. ~e report here 
our own technique of crossed ~unoelectrophoresis( which includes 
several technical improvements over the one we first described in 1974 
(35) • 
A solution of acrylamide (0.9%) and agarose (0.7%) (W/V) in 
Barbital buffer 1 0.1 ["I, pH 8.8, containing 1 roM calcium lactate was 
heated to boiling, and 21 ml of the solution was poured on a glass plate 
(85 x 85 rum). After 15 min, at 4oC, the central part of the gel (32 x 
85 ~~) was cut and removed. After completion of the isoelectrofocusing 
run, a strip (90 x 4 rom) was cut in the central part of the migration 
area of PAGIF and placed close to the edge of the acrylamide-agarose gel 
plate. The central part of the plate and the strip were covered with 7 
ml of the same acrylarnide-agarose solution to which a specific anti-APi 
antiserm had been added. After gelation, the :portion including the 
PAGIF strip was carefully covered with a larger strip of 
acrylamide-agarose, and the plate (inclusion close to the cathode) was 
submitted to electrophoresis (70 rnA per plate for 6 he) on an LKB 
Multiphor 2117-116 apparatus (LKB Application Note 85). Barbital buffer 
0.1 ill, pH 8.8, was used as the vessel buffer. After washing overnight 
in saline r the plates were dried, stained with Amido Black, and 
destained. 
The following points are critical for accurate results: 
a) The relative amount of antigen and antibody is critical and can 
produce peaks that are either too high (excess of antigen) or too small 
(excess of antibody). According to the above procedure, an optimal 
ratio is obtained when the serum used for the first dDmension is diluted 
to 0.3 mg/ml APi, and when 150 ug of specific antiserrnn is added to the 
7 ml of acrylamide-agarose filling the central part of the gel. 
b) Inclusion of the PAGIF strip inside the gel gives us more 
reproducible results than does application of the strip to the surface 
of the gel as proposed by SOderholm (62). In addition, covering the 
inclusion with a strip of acrylarnde-agarose prevents separation of the 
gel at the inclusion and suppresses endosmotic flow. 
c) The steps of the procedure must be performed as fast as possible 
to avoid any diffusion of the already focused bands. Better results are 
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, Table 2 
Composition of thin-layer polyacrylamide gels containing ampholines 
pH range 3.5 to 8 and migration conditions 
A. Gel composition (T = 6%; C = 6.8%) 
Acrylamide = 2.22 9 
N N' Methylenebisacrylamide = 0.162 9 
Double distilled deionized water = 18 ml 
Ampholines 3.5 - 5 = 1 ml 
5.0 - 8 = 1 ml 
N N N' Nt Tetramethylethylenediamine = 50 ul 
Ammonium persulfate 0.07% = 20 ul 
B. Electrode solutions 
Cathode = NaOH 1.0 M 
Anode = H3P04 1.0 N 
c. Migration conditions 
20 watts for 30 min 
25 watts for 25 min 
310 watts for 15 min 
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obtained when all the manipulation is performed at 4°C. The PAGIF strip 
must be handled carefully to avoid marks left. by fingerprinting. 
Examples of crossed liwnunoelectrophoresis performed with this 
technique are shown in Figure 2. 
2) Print immunofixation. After completion of electrofocusing runs, 
gels were placed at 4°C. A strip of cellulose acetate (Sepraphore III, 
GelrMn Instruments Co.) was soaked with specific antiserum and carefully 
transferred onto the surface of the gel. The gel was incubated for 1 hr 
at 220c and then a glass plate 'WaS put on top of the gel (still covered 
with the cellulose acetate strip). A weight was placed on the glass 
plate for 30 min to apply uniforTIl pressure. 1ne glass was then removed, 
and the gel and strip were washed separately for 16 hr in three changes 
of saline (2 liters each ti~me), stained with Coomassie Brilliant Blue 
(R250) in methanol-water-acetic acid (5:5:1), and destained in 
methanol-water-acetic acid (5:5:1). 
prelirrdnary experiments indicated that for APi the patterns 
obtained on the cellulose strips are much sharper than those from the 
gel. Thus, the development of Lmmune complexes in the strips is of 
great ~rtance. The fragility of cellulose acetate is critical. The 
strip must be manipulated carefully and must not be touched directly. 
For staining of the cellulose acetate strip one of its ends is attached 
to a metallic clip and the strip was immersed no more than 6-8 times (10 
sec each) in the staining solution and then immediately destained. 
Bending or stretching of the strip must be avoided during these 
manipulations. Excess staining will cause a dark background which makes 
the patterns difficult to interpret. 
A comparison of isoelectric focusing, crossed 
irnrnunoelectrophoresis r and print immunofixation is shown in Figure 3. 
D. Other technigpes: Several other techniques or modifications of 
the existing techniques have been reported. 
1) Modification of acid~starch gel technique. Thomas proposed a 
tube technique (63) that did not see~ to possess significant advantages 
over flat bed acid-starch gel electrophoresis. ~be other modifications 
are mainly concerning buffers: Kueppers (64) uses an EDTA buffer, and 
Cook (65) different concentrations in starch and buffers. A very 
important improvement that was developed in the acid-starch gel 
technique is obtained by Dnmunofixation as a second step. The patterns 
are clearer and sharper, and this technique can be used as an 
alternative to crossed immunoelectrophoresis, with the advantage of 
immunofixation before the latter (66). . 
2) Agarose electrophoresis at pH 8.6. This technique, first 
introduced by Laurell (67) and Fagerhol and Laurell (68) in combination 
with crossed ~noelectrophoresis, permits separation of several 
variants. It is eSp2cially useful to identify r-1S and MV phenotypes and 
certain fast phenotypes. Its combination with bTImunofixation permitted 
Johnson (69) to identify several M variants, although the problem of M 
variants still requires a precise comparison and clear-cut nomenclature 
(see Chapter 2). 
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Comparison of print liTh~nofixation (A), crossed ~~uno­
electrophoresis (B), and thin-layer isoelectric focusinj (C) 
of four different pi phenotypes. In A and C, anode at the 
left. In B, first dir~nsion, anode at the lefti second 
dimension, anode at the top. 
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3) Acid agarose gel electrophoresis. Four years ago, Laurell and 
Persson (7£a) reported a new technique which can be used in combination 
with crossed ~unoelectrophoresis to identify several Pi variants. 
Nevertheless, its advantages over acid-starch gel electrophoresis and 
isoelectric focusing are not striking, and to our knowledge it has not 
been used outside the laborato~ that described it. 
4) Cellulose acetate electrophoresis. This method was recently 
suggested by Harada (71). Its major advantage is facility. 
E. Pitfalls and Problems of Pi TYPing: 
1) Serum alteration. APi is a very labile protein, and several 
factors can alter its pattern both in isoelectric focusing and in 
acid-starch gel. TWO kinds of modifications of Pi types are frequently 
noted: 
a) Fast migrating pattern. Two banos are super~posed on the 
normal pattern, a band below M4 and a band above M6 (Fig. 4). This 
pattern could easily be ildsinterpreted as a fast variant (72). A normal 
pattern is restored after incubation of the serum for 20 rrdn with 2 
drops of 5% B-rnercaptoethanol as suggested by Cook (65). The origin of 
this denaturation is not known, nor why rrercaptoethanol treatment 
restores a normal pattern, although it could involve a thiol-disulfide 
interchange. 
b) Slow migrating patterns. Additional slow bands can be seen in 
stored sera that are not present in fresh samples. They are especially 
confusing because they interfere with the position of the slow bands of 
the deficient Sand Z phenotypes. Their multiplicity is clearly 
revealed when print ~unofixation or crossed ~noelectrophoresis is 
used as a second dimension, which demonstrates the existence of a serum 
alteration. we found a high level (25%) of such alteration in a series 
of sera from patients with IgA deficiencies (73). These sera had been 
frozen and thawed several times for different purposes. All of them 
(but none of the ones with clear-cut patterns) were found to be 
contaminated by Lactobacillus sp. and Enterobacter aerogenes. To study 
the effects of physical factors versus bacteriological factors 
contributing to the deterioration of serum APi, sera of different 
phenotypes were drawn aseptically and divided into aliquots. Repeated 
freezing and thawing of sera and storage at +4oC for as long as one 
month did not affect the phenotype. In contrast, contamination of 
aliguots with the bacteria altered the serum samples, causing a change 
in the pattern of APi in as short a time as 48 hr despite storage at 
+4oC. The new pattern obtained after both accidental and artificial 
contamination is probably due to the removal of sialic acid residues 
from the APi I11C)lecule as suggested by Nyerowitz (74), for neither TIC 
nor ~unologically reactive APi is modified, although the pattern is 
modified. Some examples of such alteration are given in Figure 5. 
'lhe above problems arise in the case of stored sera.. They 
emphasize the importance of fresh serum samples for pi typing, or 
aliquots obtained without any preservative agent and thawed only once 
for the identification. One must emphasize that certain variant 









Comparison of crossed ~unoelectrophoresis (A,D) and print 
immunofixation (B,E) obtained from altered f1 sera (slow 
pattern). In C and F, print immunofixation of a normal H 
control is given as reference. Note the shift in APi patterns 
toward the cathode in case of serum alteration. This shift 
could be confused for the presence of a slo,tl (deficient) 
phenotype. In B,C,E,F, anode at the left. In A and D, first 
dimension, anode at the left; second diIT2nsion, anode at the 
top. 
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the P and Z alleles (75). Other samples can be stored for several years 
without deterioration. For example, the s@ne 8M standard (generous gift 
of Dr. J.P. ~artin, INSERM U 72, Bois Guillaume, France) has been used 
In our laboratory for more than three years. 
F . l·1icrodensi tometry: 
This technique, permitting a quantitative determination of the 
components of pi phenotypes, was first applied to APi phenotyping by 
Allen (60). The pattern obtained from direct densitometry of 
isoelectric focusing can be clearly superimposed on those obtained by 
crossed bnffiunoelectrophoresis from focusing of the same gels (Fig. 6). 
Nevertheless, interference of the pi types with other proteins, 
including haptoglobin, Gc component, and other fast-migrating proteins 
of isoelectric point between 4.5 and 5.5 (76), cannot be eliminated by 
microdensitometric scan. This technique is of major interest when 
applied to specific bands fixed in cellulose acetate strips after print 
~unofixation, and the resolution of microdensitometry is much better 
than that obtained ~ crossed immunoelectrophoresis (Fig. 6). 
G. Suggested procedure to be applied for accurate determination of 
APi status: 
The recommended procedure is summarized in Table 3. Its complexity 
arises from the need for clear separation of the different Pi types. 
The increasing number of variants described, especially when studied 
using isoe1ectric focusing, makes interpretation of Pi phenotypes rather 
difficult. Although isoelectric focusing clearly has major advantages 
over acid-starch gel electrophoresis, it has the inconvenience of its 
advantages and, since it allows the differentiation of several variants' 
not recognized before (see Chapter 3), it complicates the work of the 
interpreter. For this reason we feel that pi determination must be 
restricted to reference centers that possess the different techniques 
suggested above, and are able to do them routinely, having a collection 
of reference sera and being in contact with other specialized 
investigators. In this context, Pi typing can be compared with other 
genetic and immunological typing techniques such as Gn, Am, and HIA type 
determinations. The association of some pi types with various diseases 
increases the importance of their accurate determination. In addition, 
the interest of using fresh serum samples and performing complementary 
family studies is again emphasized. 
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(PAGIF) applied to alpha-I-proteinase inhibitor (AIPi) phenotyping. 
II. Lmmunochenucal procedures. In: Isoelectrofocusing and 
Isotachophoresis. B.J. Radola and D. Graesslin, Eds. Walter de 
Gruyter, Berlin-New York, 265-272, 1977. 
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Chapter 2 
ALLELES AND PHENOTYPES OF THE pi SYSTEM 
It is now established that two autosomal cooominant alleles code 
for APi polymorphism, which is expressed in the individual as the Pi 
phenotypes (77). Since the first report of Eriksson in 1965 (78) I more 
than 25 alleles have been discovered, which are differentiated according 
to their position in discontinuous acid-starch gel electrophoresis (79) 
or after separation by isoelectric focusing techniques (80,81). The 
alleles described to date are indicated in Table 4. Their 
identification is still complicated, however, ~ the presence of the 
so-called M variants (Table 5). Some of the alleles are associated with 
decreased serum levels of APi (Table 6). In addition, a null variant 
allele, Pi null or pi (-), has been described by Talamo (82), and 
further reports have confirmed the existence of this allele in the 
homozygous (83-85) or heterozygous state (86,87). 
The expression of these alleles results in phenotypes. Only 45 of 
the more than 400 possible combinations have been reported to date (88). 
The allele combinations currently recognized are shown in Table 7. Two 
reports have suggested that there may be linkage between pi phenotypes 
and Gm allotypes present on ~unoglobulin gamma heavy chains (89 1 90), 
but this question remains uncertain (91). Linkage between Pi and 
erythrocyte alkaline phosphatase (ACPR) has also been proposed (92) but 
has not been confirmed in a more recent study (93). In addition, we 
have recently reported a departure from Hardy-Weinberg equilibrium in 
sera obtained from a large population of blood donors and studied by 
isoelectric focusing (94); and the transmission of the deficient alleles 
(8 and Z) seems to be more ~rtant than that of the M allele (95). 
These observations could indicate that the inheritance of the alleles of 
the pi system is more complicated than the simple autosomal codominant 
rroCie .. 
I. The M Variants 
A. hvidence for a common M variant, M Cathodal (Me): Refinement 
of the isoelectric focusing technique in our laboratories has enabled us 
to recognize a variant of the M allele which is characterized by 
duplication of all the bands constituting the mdcroheterogeneity. We 
have called this variant M cathodal (Me) (96). It may be similar or 
identical to other M variants, MB, ML, and M2 reported recently by 
others (97-99). In addition, it is possible that the allele described 
as N by Constans (100) could in fact correspond to the Me allele. The 
distibution of this new allele varies between 10 and 15% in the previous 
report of Hoffman (97) and 22% in our own studies (Table 8). we have 
observed this allele in combination with the majority of the other 
alleles (E,D,F,G1I,M,P,Q,S,V,W,X,Z) and in the homozygous state (McMc) 
Some examples illustrating the pattern of this variant in different 
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Table 4 
Alleles of the pi system 
Designation Reference 
B 11artin 1 J.P., Vandeville, D., Ropartz, C. Biomedicine 19:395-398, 
1973. 
C Robinet-Levy, M. Quoted by Fagerhol, M.K. In: Protides of the 
Biological Fluids (H. Peeters, Ed.) Pergamon Press, pp. 34-37, 
1975. 
D Robinet-Levy, M., and Rieunier, M. Rev. Franc. Transfus. 15:61-72, 
1972. 
E Fagerhol, M.K. Poumon Coeur 27:41~51, 1971. 
E2 Fagerhol, M.K. In: Protides of the Biological Fluids {H. Peeters, 
Ed.) Pergamon Press, pp. 36-37, 1975. 
F Fagerhol, M.K., and Braend, H. Science 149:986-987, 1965 
G Fagerhol, M.K. Poumon Coeur 27:41-51, 1970. 
I Fagerhol, M.K. Acta Pathol. Microbicl. Scand. 70:421-428, 1967 
L Vandeville, D., Martin, J.P., and Ropartz, C. Humangenetik 
21:33-38, 1974. 
M Fagerpolt M.K.; and Hauge, H.E. Vox Sang. 15:396-400,1968. 
N Cox, D.W., and Celhoffer, L. Can. J. Genet~~Cytoi. 16:297-301, 
1974. 
S Fagerho1, M.K., and Hauge, H.E. Vox Sang. 15:396~400, 1968. 
V Fagerho1, M.K. Acta Pathol. Microbiol. Scand. 70:621-628, 1967. 
W Fagerhol, M.K., and Tenfjord, O.W. Acta Pathol. Microbial. Scand. 
72:601-608, 1968. 
W2 Cook, P.J.L. Ann. Hum. Genet. (London) 38:275-287, 1975. 
X Eriksson, S., and Laurell, C.B. Acta Chern. Scand. 17(suppl. I}: 
150-153, 1963. ~ 
Y Cook, P.J.L. Ann. Hum. Genet. (London) 38:275-287, 1975. 
Y2 Cook, P.J.L. Ann. Hum. Genet. (London) 38:275-287, 1975. 
Z Laurell, C.B., and Eriksson, S. Scand. J. Clin. Lab. Invest. 
15:132-140, 1963. 
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Johnson, A.M. J. Lab. Clin. Med. 
87:152-163, 1976. 
Johnson, A.M. J. Lab. Clin. Med .. 
87:152-163, 1976. 
Cox, D.W., In: Protides of Biological 
Fluids (H. Peeters, Ed.) Pergamon Press, 
pp. 375-378, 1975. 
Lieberman, J., Gaidulis, L. , Klotz I S.D. 
AIDer. Rev. Resp. Dis. 113:31-36, 1976. 
Kueppers, F. Amer. J. Hum. Genet. 
28:370-377, 1976. 
Frants, R.R., Eriksson, A.W. Hum. Hered. 
26:435-440, 1976. 
Van Den Broek, W.G.M., Hoffmann, J.J.M.L., 
nijkman, J.N. Hum. Genet. 34:17-22, 1976. 
Arnaud, P., Chapuis-Cellier, C., Creyssel, 
R. , Fudenberg l H.H. Clin. Res. 25:20A, 
1977. 
Chapuis-Cellier, e., Arnaud, P. in 
preparation, 1977. 
*There is strong evidence that M Malton and M Duarte nay be identical. Similarly, MIl M2, Mn, 















Not reported 0.1% 
72% 3-6% 






Fagerhol, M.K., and Hauge, H~E. Vox. 
Sang. 15:396-400, 1968. 
Fagerhol, M.K., and Braend, M. 
Science 149:186-187, 1965. 
Fagerhol, M.K., and Tenfjord, D.W. 
Acta Pathol. Microbial. Scand. 
72:601-608, 1968. 
Laurell, C.B., and Eriksson, S. 
Scand. J. Clin. Lab. Invest. 
15:132-140. 1963. 
Talamo, R.C., Langley, C.E. 1 Reed, 
C.E., and Makino, S. Science 
181:70-71, 1973. 
Table 7 
pi alleles and resulting phenotypes 
• • •• • • • 





The alleles are indicated on the abscissa and ordinate. Their 
combination results in the corresponding phenotypes. Those 
r eported in the literature or found in our laboratory are 
i ndicated by black squares. In addition( the deficient alleles 
are des ignated \Alith asterisks. 
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Table 8 
Distribution of Mb and Me in a population 












*The frequencies of ~ and MbMc are not reported due to the 
difficulty of accurate differentiation between these phenotypes. 
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combinations are shown in Figu~e 7. Me represents the most common 
variant after Pi M. we have not directly compared Me with M Baldwin or 
M Lamb, two M variants recently reported by Johnson (102), but M Lamb 
is, in contrast to Me, associated with decreased levels of APi, and M 
Baldwin is very unusual. 
B. The MB Variant: The improved technical conditions have also 
allowed recognition of another variant whose migration is slower than 
that of M but faster than that of Me, and for which we propose the 
designation MB- Some examples of this new allele are shown in Figure B. 
A parallel study, conducted in France by c. Chapuis-Cellier, has 
determined its distribution in a normal population (Table 8). Family 
studies also conducted in France indicate that this allele is, as the 
other alleles of the pi system, transmitted in the autosomal codominant 
mode. The routine recognition of this allele requires, in addition to 
precise technical conditions described above,- special expertise in 
interpretation to prevent its confusion with M or Me. Commercial 
production of Arnpholine of a more restricted pH range would facilitate 
the recognition of this variant allele. 
II. Distribution of Pi Phenot~s and Alleles 1n Normal Populations 
Several investigations conducted in different countries are 
reviewed in Table 9 (1~3-129). They represent serum samples obtained 
from more than 30,000 subjects. The distribution of the corresponding 
allele frequencies is given in Table 10. Attempts to compare the 
results obtained in these reports are hindered by the relatively 
insensitive techniques employed in earlier studies and the different 
population groups selected, i.e., healthy blood donors, students, or 
random populations. Nevertheless, an overall picture emerges from these 
results. First, the ~rtance of ethnic variations between the 
populations according to their origin is readily apparent, i.e., the 
high frequen~ of S alleles and phenotypes in Spain and Portugal 
(118,121,122), and the scarcity of variant phenoptypes in Blacks and 
Asians (112,118,123). We have already published our results of pi 
phenotypes in two different populations (105,109) and present here two 
original studies (Table 11), one conducted on sera from a region of 
France (presumably a relatively homogeneous population) and using 
healthy blood donors, the other in south Carolina, based on the study of 
several population groups. In these studies, M variants have been 
listed as M, to permit comparison with previous reports. It should be 
emphasized that populations studied using isoelectric focusing 
demonstrate a greater frequency of variant alleles due to the higher 
resolving power of this technique when compared with that of acid-starch 
gel electrophoresis. 
III. Correlation Between pi Phenotypes and Serum Values of APi 
In the second series of pi phenotypes in Lyon, we undertook 
systematic correlation of serlli~ APi values with the phenotypes. The 
results aLe indicated in Table 12. The expected values for the 
different alleles are shown as a percentage of APi values. These 
results'are in good agreement with those reported in the literature, 
especiallY for the Z allele (130,131). It can be observed that the 
values obtained from serum APi in ZZ patients, particularly in those 
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", 
Fig. 7. Patterns of the Mc variant (anode at the top). Note the 
slight displacement of the Nc allele product both in 






Patterns of the Nb variant (anode at the top). The rvIbQ 
phenotype was provided by the courtesy of Dr. J.A. Pierce 
(St. Louis, Mo.). 
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TABLE 9. Pi PHENOTYPES IN THE LITERATURE 
PHENOTYPES REF ETHNICITY YEAR If CASES }1M MS FM MZ 
KELLERMAN 106 ICELANDERS 1970 94 75.53 2.13 20.21 
GERMANS 516 78.68 3.29 14.34 0.58 
GREEKS 400 92.50 0.50 2.50 1.75 
HUNGARIAl~S 172 82.55 1.74 9.88 0.58 
IRANIANS 271 80.44 2.58 10.33 2.21 
PAKISTANIANS 53 92.45 ----- 3.77 1.89 
INDIANS 430 99.06 ----- ----~ 0.69 
KOREANS 90 98.89 ----- -----
NEGROES 214 97.08 0.30 1.80 
V AL'lDEVILLE 107 BLACK BANTU 1974 132 93.96 ----- -----
MORIN 108 FRENCH 1975 394 81.10 12.70 1.52 3.60 
ARNAUD 109 FRENCH 1977 1653 82.39 11.19 0.12 2.60 
ARNAUD 105 FINNISH 1977 548 93.20 3.50 0.40 2.70 
HOFFMAN 97 DUTCHS 1976 1474 91 .. 66 2.85 0.28 2.24 
COOK 110 BLACKS 1975 424 97.64 0.23 0.23 1.18 
INDIANS 395 96.96 ----~ ~---- 2.02 
ARAB 85 96.47 ----- ----- 3.53 
ORIENTAL 72 91.67 ----- ----- 8.33 
WEBB III NEW YORK/USA 1973 500 88 .. 40 6.00 1.00 3.60 
McDERMID 112 INDONESIAN 1973 166 95.18 1 ... 22 ........ -~ ..... 
THOMAS 113 GERMANS 1971 1052 95.20 3.30 0.30 0.50 
KIRK 114 NEW GUINEA 1973 199 99.00 0.50 -----
VANDEVILLE 115 FRENCH 1972 944 96 .. 03 3.21 1.18 0.21 
AMER. INDIAN 230 89.13 6.96 1.30 0.411 
HARADA 116 JAPANESE 1970 965 96.80 0.50 2.50 
AINU 228 95.80 O.llO 3.80 
USA 261 91.20 3.10 4.50 
FAG ERH OL 103 NORWEGIANS 1967 2830 89.75 4.09 2.54 2.86 
COOK 110 CAUCA.SIANS 1975 5237 88 .. 65 7.65 0.61 1.74 
GOEDDE 117 GERMANS 1970 262 93.51 4.58 ----- 1.91 
FAGERHOL II? SPANISH 1968 378 75.40 18.78 0.53 1.85 
PORTUGESE 39 71 .. 79 29.20 -----
EUROPE 186 93.01 5 .. 38 ----- 1.07 
LATIN-AMERICA 26 88.46 11.53 -----
ASIA 68 100.00 ----- ~----
McDERMID 119 S. AFR. INDIANS 1971 187 97 .. 33 2.14 0.53 
FERTAKIS 120 GREEKS 1974 504 92.86 5.15 0.60 0.20 
GEADA 121; PORTUGESE 1976 219 86.30 8.22 ----- 2.74 
MARTIN 122 PORTUGESE 1976 330 76.60 16.60 ----- 3.00 
LIEBERMAN 12'3 CALIF/USA/HHITE 1976 1380 87.91 8.01 0.22 2.46 
BLACK 196 97.85 1 .. 61 -----
MEXICAN 127 90.95 8 .. 27 -----
BLUNDELL 124 IRISH 1975 1000 87.80 7.30 0 .. 30 3.50 
PIERCE 125 MISSOURI/USA 1975 2285 90.24 6 .. 43 0 .. 44 2.19 
FAGERHOL 104 LAPPISH 1966 770 98.83 0.39 ----- 0.78 
FINNISH 223 99.11 0.89 -----
McDERMID 126 S. AFR .. BANTUS 1971 226 92.92 0.44 6.64 
ROBINET-LEVY 127 FRENCH 1972 1520 84.27 12.23 0.19 0.65 
GOEDDE 128 SPANISH 1973 576 76.21 22 .. 74 ----- 1.04 
FAGERHOL 104 ISLAND 1969 450 99.11 0.89 -----




















PZ sx c E- ES MN MQ NN YZ 
0.07 0.07 0.14 2.85 
0.44 
1M FF MV SZ SS FS IS ZZ FZ MX MW MP M- LP 
1 .. 06 1.06 
0.19 1 .. 35 0.97 0.58 
1.25 0 .. 25 0.75 0.25 0.25 
0.58 1.74 0.58 0.58 0.58 1 .. 16 
0.73 1.11 0.36 1.11 1.11 
1 .. 89 




0.25 0.25 0.25 0.25 
0.66 0.30 0.48 0.24 1 .. 39 0.06 0.12 0.18 









0.40 0.40 0.40 
0.21 0.04 0.07 0.14 0 .. 14 0.04 0.04 0.07 
0.10 0.23 0.34 0.02 0.04 0.02 0.02 
0.20 0.53 0.53 0.08 0.53 
0.54 
0.20 0.40 0.20 0.20 0.20 
0.45 0.91 0.91 0.45 
0.60 2.70 0.30 
0.43 0 .. 36 0.07 0.15 0.07 0.07 
0.79 
0.60 0.40 
0.22 0.22 0.13 0.13 
0.06 0.06 0.32 1.57 0.06 0.06 0.06 0.19 
0.29 0.10 0.19 
TABLE 10. Pi ALLELES IN THE LITERATURE 
REF. ETHNY M s F z OTHER ileA 
-
EUROPE 
103 NORWAY 94.63 2.30 1.33 1 .. 57 0.17 283 
104 FINLAND 99.55 ----- ---- 0.45 ---- 22 
129 FINLAND 98.55 0.48 0.10 0.67 0.20 103 
105 FINLAND 96.62 1.73 0.18 1.37 ---- 54 
104 LAPLAND 99.42 0.19 0.39 ----. 77 
ISLAND 99.56 0.44 ---- ---- -_ .... - 45 
97 DUTCH 95.58 1.60 0.18 1.20 1.44 147 
117 GERMANY 96.70 2 .. 30 ---- 0.95 ---- 26 
106 GERMANY 87.89 2.13 9.01 0.87 0.10 51 
113 GERMANY 97.34 1.90 0.19 0.33 0.14 105 
124 IRELAND 93.65 3.85 0.15 2.00 0.35 100 
127 FRANCE 91.08 7.89 0.13 0.59 0.18 152 
107 FRANCE 
108 FRANCE 90.10 6.60 0.89 2.20 0.21 39 
109 FRANCE 90.19 7.13 0.36 1.42 0.90 165 
118 SPAIN 86.64 11.24 0.26 1.19 0.62 37 
128 SPAIN 97.94 11.50 ---- 0.74 ---- 57 
121 PORTUGAL 92.00 5.48 ---- 2.28 0.23 21 
122 PORTUGAL 86.51 11.52 ---- 1.82 0.15 33 
106 GREECE 95.87 0.25 1.25 1.62 1.01 40 
120 GREECE 96.00 2.80 0.60 0.30 0.30 50 
106 IRAN 88.38 2.21 6.82 2.21 0.37 27 
110 CAUCASIANS 93.78 4.30 0.32 0.92 0.68 523 
AFRICA 
126' S . AFR. BANTUS 96.46 0.22 3.32 ---- ---- 22 
106 NEGROES 98.18 1.64 0.18 ---- ---- 27 
107 BANTU 96.97 ----- ---- ---- 3.03 13 
110 BLACK 98.34 0.12 0.12 0 .. 59 0.83 42 
ASIA 
116 JAPAN 98.30 0.30 1.40 ---- 0.25 96 
AINU 97.90 0.20 1.90 ---- ---- 23 
110 INDIAN 98.35 ---- ---- 1.01 0.63 39 
106 INDIAN 99.42 ----- ---- 0.58 ---- 43 
AMERICA 
125 US MISSOURI(W) 94.83 3.60 ---- 1.16 ---- 193 
(B) 98.04 0.98 ---- 0.49 ---- 20 
116 u.s. 95.20 1.70 2.90 ---- 0.20 26 
III US NEW YORK 93.80 3.20 0.50 1.80 0.70 50 
123 US CALIF (\-1) 93.70 4.31 0.11 1.41 0.47 138 
(B) 98.93 0 .. 81 ---- ---- 0.27 18 
~ 
OCEANIA 
114 NEW GUINEA 99.25 0.75 ---- ---- ---- 19 
PHENOTYPES 
~OPULATION if OF SUBJECTS M MS FM MZ 1M MV SZ S IS MX MP LM PZ SX MN N 
LYON, FRANCE 1867 82.81 12.80 2.36 0.65 0.05 0.16 0.70 0.05 0.27 0.05 0.05 0.05 
:HARLESTON, SC 
WHITE 1024 87.10 8.48 0.29 2.53 0.68 0.09 0.19 0.19 0.09 0.19 0.09 
BLACK 462 96.96 1.52 0.21 1.08 0.21 
ALLELES 
M S F Z OTHERS 
CYON, FRANCE 90.81 7.23 1.29 0.60 
iCHARLESTON, SC 
WHITE 93.89 4.49 0.15 1.32 0.15 
BLACK 98.80 0.75 0.45 
~ 
~M VARIANTS ARE LISTED AS M) 
Frable 12 
Serum APi concentrations (by radial ~unodiffusion) 
according to phenotype 
Phenotype Mean va1ue* 
(mg%) 
S.D. NO. tested 
M 235.48 53.88 166 
Me 250.53 55.04 64 
Mb 250.24 48.17 34 
rt~1c 237.11 57.23 81 
MS 203.33 42.50 84 
McS 218.98 54.09 51 
MbS 214.11 47.12 19 
MZ 147.17 33.14 30 
~1cZ 132.50 14.37 8 
MhZ 145.00 ----- 1 
MP 123.67 16.61 3 
McP '135.00 19.80 2 
1M 186.00 50.14 8 
IMc 189.25 46.91 4 
1M 248.00 ----- 1 
MV 210.00 ---~- 1 
S 158.54 35.97 13 
SZ 123.33 9.60 3 
IS 149.00 ---............ 1 
PZ 70.00 ----- 1 
SX 197.00 -_ ... - .... 1 
*Expected values vs. M (% of e~ression of the M allele) are for 
M 100%, l'-lc 112.8%, Mb 112.5%, S 72.08%, Z 24.99%, and I 53.96%. 
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with infantile cirrhosis, are clearly higher than those calculated from 
asymptomatic Z subjects. This can be attributed to the fact that APi 
appears to be an acute-phase reactant protein although APi levels do not 
appear to become elevated in response to stimuli such as estrogen 
treatment or typhoid vaccine (132,133). Thus, these results could 
explain the observation that APi levels in several patients in our study 
who presented with either liver involvement or chronic obstructive 
pulmona~ disease were higher than expected in association with the Z 
allele. A review of the Z pi values associated with liver disease in 
recent reports (134-138) confirns this finding. 
Serum APi values are also decreased in association with 1M 
phenotypes (Table 12). Family studies grouping 38 cases of I 
heterozygous phenotypes confirmed these results (Table 13). The 
rnicroheterogeneity of the I allele is unusual in that band 6 is 
considerably weaker than that observed with most other allele products 
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(139). In addition, our studies clearly demonstrate the existence of 
two variants of Pi I -- II (85%) and I2 (15%) -- based on a slight 
difference in the isoelectric point of all bands, a situation similar to 
that existing with respect to M and Me (Fig. 9). Both I variants are 
associated with a mean reduction in serum APi levels of 16%, a figure 
which is very s~ilar to that found for the S alleles in MS phenotypes. 
The reason for the decreased serum APi levels is at present not clear, 
although it is interesting to speculate that it may be an example of 
deficiency due to a decreased amount of one individual component of the 
rnicroheterogeneity, in this case 16. 
IV. Distribution of Pi Phenot~s in Cord Blood 
we undertook a study of pi phenotypes in cord blood for several 
reasons; 
1. A newborn population represents a random sample of a population 
for which no selection is applied to the subjects with respect to 
criteria of health (blood donors, students) or disease (patients with 
lung or liver involvement). 
2. ~he association of pi variant phenotypes with an increasing 
number of pathological conditions, and the possibility of preventing 
their appearance or mdnimizing the consequences by preventive measures 
might represent a strong argument for performing systematic pi typing at 
birth. 
3. The easy access to cord blood at birth, the ability to obtain a 
simultaneous blood sample from the mother, and the availability of at 
least part of the family at this time greatly facilitate Pi typing and 
family studies. 
The results of this prel~inary investigation, indicated in Table 
14, suggest that 
1. pi phenotypes can be readily recognized in cora blood (140). 
All the variants found have been confirmed on fresh blood samples 
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phenotypes (by radial ~unodiffusion) 
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*Mweak is an M variant characterized on isoelectric focusing by the presence of M bands in the 
norrral position, but especially weak. It is associated with low values of serum APi measured by 
radial ~unodiffusion. It seems to correspond, in the newborn, to a temporary defect in APi 
secretion. New samples obtained in four cases in this study, one month after birth, showed 
normal radial ~unodiffusion values and a normal Pi type. 
~ 
U1 
variant phenotypes of the' babies were also found in the mother in 48% of 
the cases. 
2. The ~croheterogeneity of the pi allele products is somewhat 
different from that of pi phenotypes in adults. In all phenotypes 
observed, there was a relative decrease in intensity of bands 4 and 7, 
and a relative increase in bands 6 and 8, clearly illustrated by crossed 
~unoelectrophoresis (Figure 10). These changes disappear 
progressively and the adult pattern is established in babies within one 
~nlli. 
3. In approximately 48% of the cord samples, additional bands can 
be observed (Fig. 11). They do not seem to be artifacts, for they 
persist after treatment with B-mercaptoethanol and they do not resenble 
the patterns due to serum alteration (141). Tney do not represent APi 
of different molecular weight since they are still present in the 50,000 
dalton peak after gel filtration on Sephadex G-200. In addition, they 
appear to be identical to bands of APi extracted from placental tissues 
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(142). The additional bands decrease in intensity and disappear within 
a few days following birth. These finding suggest tl1at placenta may 
contribute to APi present in cord blood by the production of molecular 
species that differ from those synthesized by the liver in adults. The 
different distribution of APi bands in cord blood has already been 
reported for the MM phenotype (143-145). It had been proposed that this 
phenomenon could be due to an insufficient sialylation of band 4 (143); 
however, during experiments involving enzymatic desialylation of APi 
with neuraminidase (Chapter 4), we have shown that the removal of only 
one sialic acid moiety causes a shift in isoelectric point of 
approximately 0.1 pH units (146), which would be readily observed in the 
thin-layer isoelectric focusing technique. Since there was no 
demonstrable shift in migration of M4 and M6, this explanation seems 
unlikely; and more recently we have found the same pattern in an adult 
serum (105)~ we propose that the basis of this fetal pattern is an 
altered secretion of the molecular variants that constitute the 
microheterogeneity. According to the hypothesis whereby synthesis of 
each band of APi microheterogeneity is accomplished by a single clone, 
this deficiency would express brunaturity of the corresponding clone at 
birth. S1milar examples have been clearly documented for TImmunoglobulin 
G and hemoglobin molecules (147) in the newborn. 
v. Conclusion 
A. The pi System as a Genetic Marker: Following the recent 
discovery of new and M variant alleles, the pi system has evolved into a 
very useful genetic marker. At a practical level, pi typing is 
inexpensive, and unlike many other genetic polymorphisms a permanent 
record of Pi types can be kept. More than 25 different alleles have 
been described, of which the most common is present in only 50% of 
Caucasian populations, and the number of theoretical combinations 
exceeds 400. Evidence suggesting linkage with Om markers further 
enhances its interest. 
B. Necessity for extensive systematic population studies of Pi 
phenotypes: ~he significance of the association of pi variant 
phenotypes with various disorders is valid only when comparison is made 
Fig. 10. 
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Comparison of crossed ~unoelectrophoresis of an adult M 
(top) and a fetal H (bottom) pi phenotype. Note the decrease 
in band M4 in the fetal sample. First dimension, anode at 
the left; second dirrension, anode at the top. 
Fig. 11. Comparison of two~ fetal f.'l patterns of APi (left) \vith t\vO 
adult H patterns (right) on isoelectric focusing. Note the 
presence of two additional bands in the fetal patterns, one 
between H4 and N6 and the other more anodal than 1>14- Also 
note the relative weakness of t-14 and t17 in th2 fetal 
patterns. Anode at the top. 
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with reference populations derived from the same geographic area, the 
same ethnic origin, and phenotyped with the same method. 
c. pi type determination in newborns: The firm association of 
deficient pi types with pulmonary and liver disease and the convincing 
evidence of the increased prevalence in several disorders of connective 
tissue (see Chapter 4) could argue in favor of systematic pi type 
deteLmination at birth. The discovery of deficient phenotypes could 
have immediate consequences in genetic counseling and preventive 
actions. The suggestion of possible substitutive therapy either using 
normal APi (148) or synthetic analogues (149) may be justified in view 
of the relatively high risk of deficient individuals developing these 
diseases (see Chapter 4). 
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Chapter 3 
STRuc'rURE AND BIOLCGICAL ROLE OF APi 
I. Biochemical Characteristics 
APi has been characterized in several biological fluids, including 
cerebrospinal fluid (150), tears (151), arrniotic fluid (152), pleural 
and peritoneal exudates (153), cervical and selninal fluids (154), and 
duodenal fluid (155). But its principal location is the extracellular 
fluids: 40% of APi is present in serum (156) at a concentration of 
2 ug/ml, and 60% is in the extravascular compartment. Alpha-2 
macroglobulin, the second protease inhibitor in importance, is mainly 
(80%) present in the intravascular compartment (156). Thus, the 
predonunant role of APi in the extravascular space is obvious. 
APi synthesis appears to be alrrost exclusively located in the liver 
(157). Its accumulation inside the hepatocyte can be shown when the Z 
allele is present (158), and the presence of PAS-positive granules has 
largely been demonstrated in this case both py conventional (159) and 
electron microscopy (160) techniques. These granules are located in the 
rough endoplasmic reticulum (160) and can easily be differentiated from 
glycogen, for they are not modified after diastase digestion (161). 
They are round or ovoid globules of diameter between 0.5 and 40 urn. 
rrhey could be confused with 1ipofuchsin deposits (162). In addition, 
they react specifically with an immunofluorescent or iromunoperoxidase-
labeled specific antiserum against APi, proving that this material is 
antigenically similar to APi (163). (Further information on APi 
retention inside the liver cell can be found in refs. 164 and 165.) 
In addition, in two cases of liver graft for cirrhosis of the liver 
with APi deficiency associated with ZZ phenotypes, the phenotype of the 
donor replaced that of ti1e recipient soon the graft, further 
demonstrating the hepatic origin of serum APi (166,167). 
In addition to its presence in liver cells in the case of Z 
phenotypes, APi can be shown in normal subjects in rnacrophages (168) and 
in platelets (169). ~vo studies have demonstrated the presence of 
granules containing an APi-related material in yolk-sac tumors (170,171) 
and in the metastasis of a hepatoma in a patient with ZZ phenotype 
(172) . 'rhe s ignif icance of the presence of APi-secreting cells othe r 
than hepatocytes will need further investigation. 
rI'he half-life of serum APi has been estimated by Hakino (173), who 
injected radiolabeled asialo-APi in huroan volunteers, to be 6 days. 
Talamo (174) injected nor~al APi in a subject with complete APi 
deficiency (Pi null) and found similar values. Recently, Miller (180) 
studied the half-life of hurnan l\Pi injected in rabbits: Nand Z APi 
variants had approxirret.ely the sarre half-life (10 hr), whereas 
asialo~APi had a half-life of only 6 min, and the half-life of the 
APi-trypsin complex was estimated at 1.5 hr. The discrepancy between 
these results and those of Makino (173) will also need further 
investigation. 
Isolation and purification of APi have been reported py several 
authors (175-191). The techniques of purification were usually a 
combination of salt fractionation, ion exchange chromatography, and gel 
filtration (176), or more recently, were based upon affinity 
chronatography (183). We report here (Table 15) a new three-step 
technique that provides a pure material suitable for structural studies 
of the corrponents of the microheterogeneity •. Another technique, 
involving concanavalin A purification of APi as a first step, is also in 
progress in our laboratory. 
The amino acid corrpositions and rrolecular weights of APi, as 
reported py several authors, are indicated in Table 16. There is good 
overall agreement between the different results, but individual 
variatio~s can be noted. 1he majority of the authors agree on the 
presence of two cysteinyl residues in the APi molecule, forming a 
disulfide bridge. Thus., the secondary structure of APi would corrpose a 
loop. 
'l°he problenl of the sugar chains of APi is rrore controversial. A 
summary of the proposed composition of the sugars of APi is given in 
Table 17. There exist important differences, especially for the sialic 
acid content, which varies from 2 to 10 residues, with an average 
content of 7 residues. Recently, Chan (186) reported in a 
well-documented stuqy the linear structure of the oligosaccharide chain 
of APi (Table 18). If this structure is confirmed, it would tend to 
indicate that the results of the majority of other authors are 
consistent with those of Chan, except for the lack of one sugar chain. 
Preliminary results in our- laboratory·indicate that one sugar chain of 
APi type M is labile and can easily be removed during purification 
steps, especially those involving gel filtration. 
In Tables 16 and 17, the amino acid and sugar compositions obtained 
from published data are compared for the M and the Z variants. No 
striking difference appears in the amino acid composition, at least when 
the different reports are compared (Table 19). Chan (177) reported that 
serum Z protein lacked one of the four sugar chains present in the M 
protein. Following this suggestion, it was proposed that the Z molecule 
lacks one arrdno acid able to bind a sugar chain, i.e., asparagine, 
serine, or threonine. The comparison of the amino acid composition of 
the M and Z proteins does not favor this possibility. A recent report 
(182) studying the results of peptide mapping of tryptic digests of M 
and Z variants indicated that the latter presents a single amino acid 
mutation, lysine instead of glutamic acid. Similarly, Owen (192) and 
Yoshida (193), studying the differences in peptide map between Pi M and 
the S variant, demonstrated the presence of a single amino acid mutation 
(valine in S instead of glutamic acid in Ivl). Thus, in the Z as in the S 
variant, a glutamic acid of the r.1 protein appears to be replaced by 
another amino acid. The basis of the polymorphism of APi variants would 
then be explained on the basis of single amino acid mutations possibly 




Starting material: 20 ml serum 
'Step 1. Removal of albumin 
Gel filtration on Ci~cron blue Sepharose 
Total protein applied on the column: 1200 rng 
Total APi applied on the column: 40 rug (APi:protein = 3.33%) 
Total protein recovered: 540 rng 
Total APi recovered: 36 mg (APi:protein = 6.66%) 
Purification: 50% 
Step 2. Isolation 
Preparative flat bed isoelectric focusing in a pH gradient 3.5-5.5 
(supporting medium: Sephadex G75 Ultroaex) 
Total protein applied on the gel: 540 rng 
Total APi applied on the gel: 36 rug (APi:protein = 6.66%) 
Total protein recovered in the selected zone: 30 mg 
57 
Total APi recovered in the selected zone: 25 mg (APi:protein ~ 83.33%) 
Purification: 76.7% 
Step 3. Subtractive affinity chromato9raphy 
An antiserum against pi null is obtained in rabbits ~ immunization with 
human serum totally deficient in APi. The globulins are obtained by 
DEAE-ce1lulose chromatography. They are linked to 6-arrdno hexyl Sepharose. 
This column binds all the serlli~ proteins except APi. 
Total protein applied on the colurrn: 30 rng 
Total APi applied on the column: 25 rug (APi:protein = 83.33%) 
Total protein recovered: 21 mg 
Total APi recovered: 21 mg (APi:protein = 100%) 
Table 16 
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7.7 44.1 2 52.4 25.9 14.0 18.9 48.5 36.5 8 29.9 18.1 21.1 30 2 
2 
6.8 26.5 56,009 
1 46 2 55 24 12 17 44 36 8 28 IB 21 30 7 23 50,50B 
.. 
180 22.1 6.8 40.8 1.8 47.1 20.8 11.8 16.3 42.4 36.9 1.6 23.9 17.7 19.7 25.6 3.1 5~2 22.2 41,00B 
181 22 7 
182 24 6 
183 23 6 
184 25 7 
18S 22 6 
186 24 . 8 
















































































































las 26.6 7.5 44.8 1.7 . 59.2 23.7 12.5 20.6 45.0 35.1 7.5 2B.2 18.3 22.5 28.5 1.8 6.9 26.8 50,009 
Z pheno~ 
177 27 12 42 51' 30 13 16 33 9 26 19 27 29 24 
178* 29.6 14.2 . 40.9 54.1 30.3 14.7 20.0 41.7 37.3 20.8 19~2 23.9 21.6 8.2 27.4 
180 22.8 7.1 41.1 1.7 45.3 19.6 12.0 15.9 42.7 38.2 7.6 23.9 19.2 20.6 27 .. 6 3.1 5.6 23.8 
182 26.3 S.9 41.S 2.4 53.9 21.7 10.5 15.6 51.7 30.9 8.2 27.2 25.9 22.8 26.4 2.1 6.1 21.2 
188 25.7 7.5 42.8 l.7 50.0 32.2 13.4 20.2 44.4 33.B 7.2 28.1 18.8 21.9 28.1 1.9 6.2 26.5 
, *lsolated from the liver. 
. . 
Table 17 

































































































Pc imary structure of the t\vO sugar chains of APi 
(modified from Chan et al., ref. 177) 
~1 
Chain A 









SA- GAL"-NAG1\ - (t1AN) 3 - (NAGA) 2 ~ ASN 
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Differences in amino acid corrposition between H and Z APi proteins 
APi Amino acid conposition (residues/lTOl) 
type 
Ala M9 Asp Cys Glu Gly His Ile Leu Lys Met Phe Pro Ser '!br "rrp Tyr Val 
K 27 8 43 54 22 12 18 44 31 9 28 19 27 33 6 24 
S 27 12 42 51 30 13 16 43 33 9 26 19 27 29 6 24 
2-ii* +4 -1 -3 +8 +1 -2 -1 -4 -2 -4 
K 26 7.1 44.1 2.0 52.3 25.9 14.0 18.9 48.5 36.5 8 29.9 18.1 21.7 JCJ 2 6.8 26.5 
. Z 29.6 14'.2 40.9 54.1 30.3 14.7 20.0 41.7 31.3 20.8 19.2 23.9 27.6 8.2 21.4 
Zwtl +l.6 +6.5 -3.2 +1.7 +4.4 +0.7 -1.1 -6.8 +0.8 -9.1 +1.1 +1.2 -2.4 +1.4 +0.9 
K 22.7 6.8 40.8 1.8 41.1 20.8 11.8 16.3 42.4 36.0 7.6 23.9 17.7 19.7 25.6 3.1 - 5.2 22.2 
Z 22.8 7.1 41.1 1.7 45.3 19.6 12.0 15.9 42.7 38.2 7.6 23.9 19.2 2a.6 27.6 3.1 5.6 2).0 
ZooM te.l +0.3 +0.3 -0.1 -1.8 -1.2 +0.2 -0.4 +0.3 +2.2 +1.5 +0.9 +2.0 +0.4 +0.8 
" 24 6 40 2 53 21 11 16 52 30 9 28 25 22 29 2 6 21 Z 26.3 5.9 41.49 2.31 53.85 21.76 10.49 15.54 51.67 30.90 8.16 27.1 25.85 22.8 28.43 2.13 6.09 21.21 
%-K +2.3 -0.1 +1.5 +0.4 +0.9 +0.7 -0.5 -0.4 -0.3 +0 .. 9 -0.8 -0.8 +0.9 +0.8 -0.5 +0.1 +0.1 +0.2 
lege 
!ere~ 
) +1.5 +2.615 -8.6 +2.975 - -1.95 - -2.975 +0.875 +0.725 --
, difference ootwe-en the two types. 
62 
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translation of the whole pattern toward the anode or the cathode. Such 
results, which will need further confirrration, especially bj the 
determination of the conplete aITtino acid sequence of each variant, 
confirm our theory of the basis of the polymorphism, proposed two years 
ago (194), which is similar to the theoretical basis of the polymorphism 
of llnmunoglobulin markers responsible for the existence of the Gro 
system. 
~wo reports (83,210) have established the partial N-terrrdnal arrdno 
acid sequence of the first residues of APi ·type M. This sequence is 
indicated in 'l'able 20. Similarly, Chan (personal comrrunication, 1977) 
has delineated the sequence of a major glycopeptide comprising 120 amino 
acids and obtained by cleavage of the APi rrolecules bj cyanogen bromide. 
The basis of the microheterogeneity inside an allele product is 
also controversial. Crawford (176) reported that a complete 
desialylation of pure APi did not modify the microheterogeneity of APi 
but resulted in a shift of the whole pattern toward the cathode. 
Partial or complete desialylation of serum APi (195-197) gave 
contradictory results. Laurell (190) recently reported that the 
rrdcroheterogeneity could result from different degrees of sialylation of 
the same molecule. In contrast, Talamo (199) suggested that after 
desialylation, serum APi still remained microheterogeneous. 
In an attempt to clarify these discrepancies, we performed a series 
of desialylations of crude serum. APi variants M and Z were separated 
before and after desialylation b¥ isoelectric focusing in a pH gradient 
3.5 - 8.0 and studied by print immunofixation. Microdensitometry of the 
prints was also perforrred. ~he protocol of the experiment is indicated 
in Table 21 and the results obtained are shown in Figure 12. Complete 
desialylation was assumed when no additional sialic acid could be 
detected py the Warren technique after hydrolysis in 1 M Hel at 8eOc for 
2 hr. Comparison of the migration patterns of the different phenotypes 
before and after complete desialylation (Fig. 12) shows the following: 
1) Microheterogeneity of APi remains identical before and after 
desialylation. This fact indicates that sialic acid does not account 
for APi microheterogeneity nor for the t-'1 variant or Z variant. 
2) The respective positions of M and Z variants before and after 
desialylation are identical. This suggests that the content of sialic 
acid for M and Z proteins is identical, and thus does not confirm the 
possibility of a rrrrssing sugar chain in the Z protein. 
3) The shift in isoelectric point for each band is identical and 
corresponds to 1.0 pH unit (+ 0.05 units). As each sialic acid 
contributes to the net charge of a molecule for 0.1 acidic pH unit, this 
result indicates that each APi molecule contains 10 sialic acid 
residues. This result is in complete agreement with ti1e recent results 
of Chan (189). ~he discrepancy between the results presented here and 
some early reports on this subject can c€ explained b¥ technical 
differences; i.e., desialylation cQula have been incomplete, and in 
addition, analysis of asialo-APi was done using acid starch gel and 




Partial N-terrninal amino acid sequence of alpha-I-protease inhibitor 
1234567 8 
NH2- GLU ASP PRO GLN GLY ASX ALA ALA (I) * 
1 2 3 4 5 6 7 8 9 10 
NH2- GLU ASP PRO GLU GLY ASP ALA. N..A GLU ASP (2) 
*(1) From Musiani (ref. 183); (2) From Johnson (ref. 210). 
Table 21 
Desialylation of APi 
1. pH adjustment of serum 
1.0 rnl of serum is dialyzed overnight against 
acetate buffer 0.1 M, pH 5.0. 
2. Neuraminidase treatment 
100 ul of serum is added to 200 ul of neurarrdnidase 
(EC 3.2.1.18) containing 500 units/ml ~ehringwerke). 
The mixture is incubated at 37OC. 
3. Analysis of the effects of neuraminidase 
Aliquots are taken at different times. They are compared 
with untreated serum using isoelectric focusing (pH 
3.5-8) followed ~ print immunofixation. 
4. Sialic acid measurement 
Total CHP digestion of serum protein is carried out in 
Hel 0.1 N at 80°C for 1 hr. The release of sialic acid 
is measured using the Warren thiobarbituric assay 
(analysis kindly perforrred by Dr. G.B. Wilson, Departrrent 





























em from Anode 
C 
Fig. 12A. {A} Serum APi desialylation. a, native Z APi; h, asialo Z 
APi; c, asialo H APi; at native M APi. (8) a, native H APi; 
band c, partially desialylated H APi; d, asialo M APi. (C) 
pH gradient in the gel related to the distance from the 
anode. pH gradient: 3 .. 5-8. Anode at the top. The patterns 







.~ ..f. . 
Print irnrrunofixation of native 
and Z APi. Anode at the top. 
M M 
(top) and asialo (bottom) r'1 
pH gradient: 3.5-8. 
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power than isoelectric focusing and print immunofixation, especially in 
this zone of pH. 
In summa~, the differences in the polymorphism between the M and Z 
molecules do not lie in sialic acid differences. Amino acid mutations, 
as the one reported py Yoshida (182,193), could be, as discussed above, 
responsible for the translation of the whole pattern. Preliminary 
experiments indicate that the S molecule after desialylation behaves 
identically to the asialo,~ and Z when compared with the intact 
molecule. All these facts are in favor of different amino acid 
substitutions in the sarre region of the molecule responsible for the 
basis of the polyrrDrphism (194). 
Similarly, the microheterogeneity cannot be explained on the basis 
of sialic acid differences. Although differences in other sugars could 
be involved in the origin of the multibanding pattern, this hypothesis. 
seems unlikely. It would be logical to propose that each band that 
constitutes the ~croheterogeneity also differs ~ single amino acid 
mutations. These bands could correspond to the expression of different 
genes at a single locus in each individual. They could also, in our 
hypothesis (194), correspond to the product of different clones, 
differentiated from an original cell qy somatic mutations, which would 
be responsible for the production of each band inside the macro-
heterogeneity of an allele product. 
II. Biological Role of APi 
As reported above, APi represents the najor protease inhibitor of 
extracellular fluids. It is known to inhibit a wide variety of 
proteases (Table 22). In normal circumstances, the major role of APi as 
antienzyme is mainly concerned with elastase and collagenase released 
from granulocytes, and with proteases of microbial origin. A role of 
APi in preventing an uncontrolled activation and inactivation of the 
coagulation mechanisms has also been recently suggested (156). The 
interaction of APi with proteases is therefore of major interest and is 
concerned with processes as vital as inflammation, infection, and wound 
healing (200). 
The interaction between APi and both trypsin and elastase has been 
extensively studied, mainly py Ohlsson (201-209). We here present the 
results of our studies on the interaction between APi and these two 
proteolytic enzymes. 
~he protocol of the e~eriments is indicated in Table 23 and the 
results are shawn in Figures 13 and 14. They deserve the following 
corrurents: 
1) In excess of APi, a complex between APi and proteases is formed. 
This complex is stable at room temperature for at least 24 hr. The 
amount of complex formed is proportional to the quantity of protease 
added (Fig. 13A). 
2) In excess of proteases, the complex between APi and proteases 
progressively disappears. It is replaced qy another pattern that is 









*?, not yet determined. 
Table 22 
Specificity of human plasma inhibitors 
Enzyme inhibition 






+ + + + + 
+ ?* 
+ weak ? 
+ weak + 
weak weak + + 









Binding of t~sin and elastase to serum APi 
1. Study of the farnation of the complex between APi and proteases 
An identical volume of serum (100 ul) is incubated at room 
temperature for 2 hr with increasing quantities of t~sin or 
elastase. The ratio of proteases to APi varies from 1/1 to 1/64. 
2. Study of the formation of APi inactivated by proteases 
100 ul of serum APi is incubated with proteases in a 1/2 molar 
ratio. Samples are taken at dfferent intervals (10-60 mQn). 
3. Analysis of APi and co~lexes 
The samples are studied qy isoelectric focusing in a pH range 3.5-8 
followed qy print immunofixation. The quantitation of the 
different forms is made py microdensitometry of the immunoprints 
(courtesy of Dr. R.C. Allen, Department of Pathology, MUSC). 
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'- .,-. 
Fig. 13A. Interaction behleen serum APi and trypsin. Print 
irnmunofixation of serum APi incubated with different arnounts 
of trypsin. Note the increasing quantitites of complex 
relative to the increasing amounts of t~sin added. The two 
patterns on the right shoN the coexistence of degraded 
product (PI) with the corrplex. Anode at the top. 
pH gradient: 3.5-8. 
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Fig .. 138. Interaction between serum APi and trypsin. Detail of the 
degradation product (PI) corrpared \'-lith native serum APi. 
Note the presence of two additional cathodal patterns, \vhich 
correspond respectively to P2 (rrore basic) and P3 (more 
acidic). Print iwrounofixation. pH gradient: 3.5-8. 
Anode at the top .. 
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Fig. 13B. Interaction between serum APi and trypsin. Detail of the 
degradation product (PI) corrpared with native serum APi. 
Note the presence of two additional cathodal patterns, which 
correspond respectively to P2 (rr.ore basic) and P3 (more 
acidic). Print iwmunofixation. pH gradient: 3.5-8. 
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Fig. 13C. Interaction behveen serum APi and trypsin. Kinetics of 
dissociation of the complex and the appear&lce of degradation 
products. rr'he relative proportions of corrplex and breakdalln 
product are calct)lated from microdensitornetric tracings of 
the irnmunoprint (courtesy of Dr. R.C. AlIenI Departrrent of 






'~"':,-,.-- . , 
Interaction bet\veen serUi11 APi and elastase. rr'he results are 
similar to those obtained ~ incubation ·with trypsin. Note 
the differ"ent isoelectric points of the corrplex and the 
breakdaNn product when corrpared with ·those resulting from 
incubation \vith trypsin. Anode at the top. pH graoient: 
3.5-8. 
TWO other patterns can be seen in addition, one more basic (P2) and the 
other more acidic (P3) than the complex (Fig. 13B). The formation of PI 
is time-dependent, and in excess of protease all the complex is 
converted to PI after 1 hr of incubation at 370C (Fig. l3C). 
3) The microheterogeneity of APi rerrains identical within these 
different patterns, indicating that these different steps identically 
affect each component of the APi rnicroheterogeneity. 
4) rr'he isoelectric point of the complex and of the different 
patterns is different for trypsin and for elastase (Fig. 14). 
Our interpretation of the results is as follows: 
1) wnen the ratio of APi to enzymes is in favor of APi, a stable 
complex is formed. The protease is trapped inside this complex and 
loses all proteolytic activity. 
2) In excess of proteases, APi is saturated. 'l'he conplex is then 
attacked by free partial proteases. The molecule of APi undergoes a 
proteolytic cleavage and gives a degraded product (PI). The modified 
APi, due either to the rerooval of an essential "trapping fragrrent" or to 
a modification of its quaternary structure, can no longer inhibit the 
protease, and the complex is dissociated. The altered product is then 
liberated ana the rrodification in charge in its primary structure due to 
the removal of the fragrrent is indicated by the change in its 
isoelectric point. 
'rhe patterns P2 and P3 could correspond respectively to the conplex 
of intact APi with two molecules of proteases, and to the complex 
between protease and degraded APi before release of the protease 
(F'ig. l3B). 
~he summary of this interpretation is indicated in Table 24. 
The difference between the isoelectric points of degraded APi after 
proteolysis py trypsin and elastase tends to indicate that the points of 
cleavage of these two enzymes on the APi molecule are slightly 
different. 
These results agree with the observation ~ Johnson and Travis 
(210) that the dissociation of the complex between APi and t~sin 
liberates an APi rrolecule whose rrolecular weight is 8000 units lCMer 
than the intact molecule.' This molecule, in addition, has lost its 
inhibitory capacity. Similarly, Lo (18?) reported that the interaction 
of APi with elastase gives two complexes of 73,800 and 58,300 daltons 
and fragments that do not inhibit enzymes, but retain immunological 
characteristics of APi. 
'lbe dose-dependent interrelatonship between proteases and APi has, 
to our knowledge, not hitherto been reported. This finding is striking, 
for it indicates that this interrelationship is based not on the 
absolute level of proteases or their inhibitors but on the ratio between 
this level. There is, at least in vitro, a "safety" level at which 




Interpretation of the results obtained from binding of proteases with APi 
1. In excess of APi 
APi + protease -) APi-protease (stable at 22°C for 24 hr) + free APi 
2. In excess of protease 
APi + protease ---> APi-protease + free protease 
APi-protease + protease ---) protease-APi-protease (pattern 1) 
protease-APi-protease ---> protease-APi* (pattern 2) 
protease-APi* ---) APi* + protease 
APi*, altered APi. 
capacity of inhibition is overcome and inhibition disappears. At this 
ratio, which even CQuld be the normal level of APi if the level of 
proteases is higher, the inhibiting capacity is inefficient. 'I'his 
"critical" level of inhibition could explain why in vivo there is no 
progressive effect of proteolytic enzymes. In fact, individuals with 
severe deficiency (ZZ) suffer from clinical disorders in the great 
majority of the cases, whereas heterozygous patients seem to be free 
from any disorder induced ~ proteases (see Chapter 4). Similarly, 
under certain acute circumstances, an excessive liberation of proteases 
could temporarily, by increasing one of the factors, produce a dramatic 
excess of proteolysis in individuals protected under normal 
circumstances. This would introduce a new pathogenesis, which would 
incluae not only the level of protease inhibitors but also the 
protease~antiprotease ratio. 
The structural variation of APi, due both to its rrdcroheterogeneity 
and its polyrrorphism, the association of decreased serum values with 
certain phenotypes of this protein, and the mechanism of inhibition of 
proteases clearly indicate the need for additional structural and 
kinetic studies on this rrajor protease inhibitor. 
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Chapter 4 
APi DEFICIENCY AND DISEASES 
The association of APi deficiency with clinical disease has given 
new impetus to the study of this protein. In addition to the discovery 
of high frequencies of pi deficient phenotypes and their possible 
relevance in pathophysiology of several disorders, these observations 
have stimulated research designed to explore the biological consequences 
of APi deficiency. 
I. Pulmonary Diseases 
In the first report on the association of pulmonary emphysema and 
APi deficiency, Eriksson (211) indicated that the incidence of chronic 
obstructive bronchopulmonary (COPD) disease was 15 times higher in 
IIhomozygous deficient" subjects than in normal populations. He reported 
also that relatives with heterozygous deficiency did not present an 
increased evidence of COPD. Soon afterwards, Fagerhol (212) studied a 
heterogeneous population of patients with pulmonary diseases and found a 
significant increase of Z deficient phenotypes, particulary in patients 
with bronchial asthma, chronic bronchitis, and pulmonary emphysema. In 
33 subjects found later to have the ZZ phenotype, 23 presented in the 
initial study of Eriksson (211) with chronic obstructive pulmonary 
disease, which in 50% took the form of extensive pulmonary emphysema. 
Several reports have confirmed the high incidence of pulmonary emphysema 
in ZZ deficient subjects. Rawlings (213) described clinical repiratory 
obstruction in 19 of 20 ZZ patients, which was confirmed by pulmonary 
function testing in 18. Identical findings have been reported recently 
by Eriksson (214). 
'I'he question of whether COPD develops in patients wi th heterozygous 
deficien~ phenotypes such as MZ remains controversial. Mitmann (215) 
indicated that intermediate APi deficien~ and MZ phenotypes occurred 
lTK)re corrrrnonly than expected among patients with COPD. However, this 
finding has been questioned in view of several reports in which neither 
the prevalence of deficient phenotypes in patients with COPD (216-218) 
nor the frequen~ of OOPO in subjects with deficient phenotypes was 
found to be elevated (219,220). Nevertheless other documented reports 
found a definite association (221,222). Differences in evaluation of pi 
types in population samples or in the diagnosis of pulmonary disorders 
could explain the discrepancies in these documented reports. The 
incidence of other phenotypes in COPD is less well documented. One 
report (222) indicated that MS heterozygotes do not seem to be 
predisposed to pulr~nary diseases. The association of the S allele with 
the Z allele is, according to Larsson (214), a strong predisposing 
factor. Finally, the three cases in which a null phenotype of APi was 
reported suffered from extensive pulmonary emphysema (223-225). These 
findings strongly indicate that deficien~ of APi is the major cause of 
lung involvement in APi deficiency. The use of several experimental 
anilnal models confirms the importance of a balance between protease and 
antiprotease in the maintainance of lung integrity (226-234). 
II. Liver Diseases 
A. Neonatal cirrhosis: Since the first report by Sharp (235) of 
the association of neonatal jaundice and APi deficiency of the zz type, 
several reports (236-239) have clearly established this relationship. 
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It appears that the presence of the Z allele is essential, but this 
disorder can be found in the heterozygous state (240). The prognosis 
associated with such liver diseases is not clearly established. In 
contrast to at least one previous study (231), recent reports indicate 
that the prognosis in these children is more hopeful. In a follow-up 
survey of 18 patients presenting with this syndrome, Moroz et ala (242) 
reported that 6 have died of cirrhosis, 3 have severe liver disease, but 
11 have relatively little evidence of liver disease. Similarly a recent 
study by Hadchovel (243) ex~ned the histological appearances in liver 
biopsies obtained in the first six months of life from 15 children with 
neonatal choleostasis of the zz type. The severity of the prognosis 
appeared to be closely related to the histological picture. Five 
patients reported by Hirschberger with neonatal hepatitis syndrome and 
pi ZZ phenotype are all alive, and three are asymptomatic (244). 
The proportion of children with the ZZ phenotype developing a 
neonatal hepatitis syndrome has been debated. In an exhaustive study of 
200,000 neonates in Sweden, Sveger (245) found 120 children with the zz 
phenotype. Prolonged obstructive jaundice was found in 14, of which 9 
had both clinical and laboratory evidence of severe liver disease, and 5 
had only laboratory evidence of liver involvement. Eight others had 
rrdnirnal laboratory abnormalities and variable clinical complaints. 
Thus, the frequency of children with Pi zz presenting with liver 
involvement at birth was only 16%. An additional factor is presumably 
necessary for the development of liver disease. Conversely, two-thirds 
of the children with cirrhosis following a history of neonatal hepatitis 
are deficient in APi (Pi type ZZ) (246). 
B. Adult cirrhosis in patients with zz pi type: This association 
seems to be very frequent. In a previous study, Berg and Eriksson (247) 
reported ex~nation of hepatic tissue in 14 ZZ patients. Cirrhosis and 
fibrosis were clearly present in 8 cases. Additional reports have 
confirmed this association (248,249). Nevertheless, a deficiency of APi 
of z type does not seem to account significantly in the general etiology 
of common cirrhosis (250). 
III. Other Diseases 
Several other diseases or syndromes have been reported in 
association with APi deficien~ of the Z type. They are indicated in 
Table 25. Further studies will be necessary to determine whether these 
associations are merely fortuitous. 
Table 25 
Diseases or syndromes in which APi 
deficiency has been reported 
Disease or syndrome 
Glomerulonephritis 















Type of APi deficiency 
zz 
Decreased serum levels 
ZZ 
pi null 
MZ and ZZ 
Decreased serum levels 
variant pi types 
Deficient Pi types 
ZZ 
MZ 
Deficient Pi types 
MZ 
HZ and ZZ 

















IV. Personal Results 
We present here our results on the frequen~ of deficient Pi types 
in association with several clinical disorders. 
A. Asthma in Children: A detailed report on this study in 298 
children with asthma has already been published (279). The results can 
be summarized as follows: 
1) Higher frequency of pi deficient phenotypes (I,S,P,Z), 22.5%, in 
children with asthma as compared with 16.3% in a normal population of 
the same geographic origin. 
2) Greatly increased frequen~ of deficient phenotypes in nonatopic 
asthma (46.2%). Normal incidence in atopic asthma (15.9%). 
3) Significant effect of deficient phenotypes upon the age of 
onset, the severi~ of the disease, the presence of hyperinflation, and 
the existence of abnormalities of pulmonary function. The significance 
of these results has been discussed (279). 
B. Hemochromatosis: In primary idiopathic hemochromatosis the 
incidence of hepatocellular carcinoma is high (280), and recently an 
elevated frequency of the Z allele (60%) has been reported by Janus and 
Carrell in 10 patients with this disease (276). We have therefore 
undertaken Pi typing in a larger series of patients with primary 
h~nochrornatosis from the Southeast and Midlands of England. Since no 
control figures using this technique are available from the same 
geographical area, we have compared our results with those obtained from 
two large series. The first, published by Cook, included healthy 
subjects from the same regions but typed by acid-starch gel 
electrophoresis (281), and the second consisted of a group of French 
controls in whom pi types \~re determdned ~ isoelectric focusing (282) 
(Table 26). 
There was no significant difference in the distribution of the 
various phenotypes between the patients and the two control series. In, 
particular, we found the Z 'allele (MZ phenotype) in only one (2.5%) of 
the 41 patients. This contrasts sharply with the figure of 60% found by 
Janus and Carrell (276), suggesting that the Z allele is not a 
predisposing factor, at least in our patients, in the initiation of the 
disease or the subsequent develo~~ent of hepatocellular hepatoma. 
c. Juvenile chronic polyarthritis: Breakdown of articular 
collagen is an ~~rtant feature of arthritic joint damage (283), and 
this in part appears to be due to an increased activity of synovial 
collagenases (284,285). It is possible that deficient activity of 
protease inhibitors could be a predisposing or aggrevating factor in the 
pathophysiology of joint damage. An increased frequency of Z phenotypes 
has been reported recently in adults with rheunatoid arthritis (286). 
We have investigated the hypothesis that deficient alleles may be more 
common in children with juvenile chronic polyarthritis (JCP). we 
studied 96 patients with JCP. 1he criteria for the diagnosis were as 
defined by Ansell (287): (a) onset before age 16; (b) involvement of 
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patients and controls 
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M MS HZ 
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and/or limitations of movements; (c) if fewer joints are involved, 
histology showing changes compatible with rheumatoid arthritis; and. (d) 
exclusion of other disorders in the first year of disease, including 
ankylosing spondylitis, psoriasis, ulcerative colitis, and systemic 
lupus erythematosis. At the time of the blood sample, the mean age of 
these 96 patients was 5.4 years (9 months - 15 years) and the 
female:male ratio was 2.7 (7~ F : 26 M). Twenty had commenced as a 
systerrdc illness going on to polyarthritis; chronic iridocyclitis was 
present in 35 and amyloidosis in 20. A small number of cases had more 
than one of these features, i.e., 2 with chronic iridocyclitis also had 
amyloidosis. In 58 cases we also examined sera from the patient's 
father and mother, and parentage in each case was confirmed by Qu, Am, 
Inv, and HLA typing. 
The distribution of APi phenotypes in JCP was compared (Table 27) 
with that found in the two control series utilized for the 
hemochromatosis study. The frequency of Z phenotypes was significantly 
higher in the study gcoup than in controls (P < 0.001). The frequency 
of the S phenotype was also elevated, although this difference was not 
statistically significant. The distribution of the other phenotypes, 
and in particular the Me allele, did not differ appreciably from control 
values (Table 28)~ 
Tne genetic transmission of APi alleles was studied in 58 cases. 
In the case of Sand Mc, alleles were inherited in random fashion 
equally from mother and father, supporting the concept of autosomal 
codorrdnant transmission (288). In contrast, the Z allele was 
transmitted to the patient from the father in all but one family 
(Table 29). 
The striking abnormality in this study is the increased prevalence 
of Z phenotypes in JCP. This is an important observation, since APi is 
known to inhibit the activity of collagenases as well as neutral 
proteases (see Chapter 3), which are involved in arthritic joint damage 
(284), and APi levels in synovial fluids are elevated in some cases of 
rheumatoid arthritis (289). In patients with deficient phenotypes, 
however, the serum level of APi is much lower, and since this level 
parallels the amount found in synovial fluid (289), the latter would be 
expected to be markedly reduced. Since the mechanisms of inhibition 
include formation of complexes between APi and proteases (290-292), low 
levels of APi would result in increased amounts of protease remaining 
unbound and active. Furthermore, we have shown that such unbound 
proteases can act upon formed complexes causing their dissociation, 
denaturation of APi, and the release of additional biologically active 
protease (see Chapter 3). The increase of the S allele frequency, 
although not significant, may also be involved in tile pathophysiology of 
protease inhibition in JCP, since it is associated with decreased 
amounts (20%) of serum APi (293). 
The clinical relevance of this increase in Pi deficient phenotypes 
is not clear. No difference in distribution of Pi types was apparent 
when patients were subdivided with respect to clinical complications 
such as amyloidosis, systemic involvement, and iridocyclitis, although 
the frequency of S phenotypes was high in patients who had developed 
amyloid. Similarly, an influence of deficient phenotypes on the age of 
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Table 27 
Comparison of APi distribution in juvenile chronic 
polyarthritis and in two control populations 
Number M MS MZ FM 
JCP 
(isoelectric focusing) 96 73.95 14.58 10.41 1.06 
United Kingdom 
controls (225) 
(acid-starch gel) 4565 88.50 8.00 1.60 0.70 
French controls 
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Transmission of the 
variant alleles 
Patients Father Mother 
9 5 4 
13 6 7 
7 1 
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disease onset is not evident in our study, and we did not find any 
significant association between pi alleles and other genetic markers 
(Qn, AIn, Inv, HIA), although the numbers studied may have prevented the 
recognition of such a relationship. The result of our family study 
revealed a predominantly paternal transmission of the Z allele. 
Speculation concerning this interesting finding must await studies of 
larger number of families. 
JCP is the second rhellnatic disorder in which an elevated frequency 
of deficient phenotypes of APi has been reported, but investigation of 
other disease groups may reveal additional examples. Indeed, our 
preliminary investigations show that the frequency of the Z allele is 
also elevated in juvenile ankylosing spondylitis. Detenmination of pi 
types may prove in the future to be useful in genetic counseling, as 
well as in the diagnosis (e.g., we have found no increase in abnormal Pi 
types in scleroderma), management, and prognosis of patients with 
rheumatic disorders, in addition to providing further information 
concerning the pathogenesis and the possible hereditary transmission of 
these diseases. 
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D. Carcinoma of the lung: we have determined APi serum 
concentrations and pi phenotypes in 123 patients (105 males, 18 females, 
ages 29-84 years, mean age 62.8 years) from Lyon, France, presenting 
with histologically proven squamous cell carcinoma of the lung. APi 
serum concentration was determined by radial ~nodiffusion using 
commercial plates (Behringwerke GMBH). The results in the cancer 
population were compared with those obtained in healthy blood donors 
from the Sru~ geographic area. The results of Pi phenotypes are 
indicated in Table 30. In Table 31, the allele frequency in the two 
populations is compared, and in Table 32 the rrean values of serum APi 
are indicated. Statistical analysis of these results (294) indicates 
that the frequency of MZ phenotypes is significantly increased (P < 
0.05) in the squamous cell carcinoma population. Similarly, the 
frequency of the z allele is significantly increased (P < 0.01). Study 
of APi serum concentrations by analysis of variance indicated that 
values in both non-MZ and MZ populations are significantly increased in 
comparison with levels in normal subjects (P < 0.001), but this increase 
is less in patients with MZ phenotypes than in patients with non-MZ 
phenotypes {P < 0.00l}. 
'l'he significantly higher proportion of heterozygous MZ deficient 
phenotypes in patients presenting with squamous cell carcinoma of the 
lung is a striking feature. In two recent publications (295,296) a 
relatively high incidence of MZ phenotypes was reported in patients with 
squamous cell carcinoma (8.7%) and with lung cancer (6.3%), but due to 
the small number of cases studied, the values did not reach statistical 
significance. calculation of the relative risk of squamous cell 
carcinoma in our patients possessing a Z allele indicates that it is 
3.05 times greater than the risk associated with the presence of other 
alleles. 
Several hypotheses could be proposed to explain this association: 
(a) a genetic mechanism in which the Z allele could be linked with other 
genetic factor(s) whose expression could be associated with a greater 
susceptibility to this kind of cancer; or (b) a biochemical mechanism in 
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Table 30 
APi phenotypes in patients and controls 
Subjects Number . Phenotyp= distr ibution (%) 
'M MS MZ s sz Other 
Lung cancer 123 75.61 14.63 6.50 0.81 0.81 1.63 
patients 
Controls 1867 82.81 12.80 2.36 0.70 0.16 1.17 
92 
Table 31 
Distribution of APi Z phenotypes and of Z alleles 
in lung cancer patients and controls 
Subjects Number Phenotype distribution (%) Allele frequency (%) 
MZ, sz Other Z Other 
Lung cancer 123 7.31 92.69 3.65 96.35 
patients 
Controls 1867 2.52 97.68 1.28 98.71 
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Table 32 
Serum levels of APi 1n lung cancer patients and controls 
Subjects Number Serum APi (rng%) Standard deviation 
Lung cancer 
patients 
MZ 8 299.6 110.8 
Other 115 419.5 177.9 
Controls 
MZ 30 167.2 33.2 
Other 320 218.5 57.3 
which APi deficiency would favor cell transformation. Indeed, in vitro 
studies have demonstrated a role of proteases in cell division (297) ... 
uncontrolled proliferation, and increased rragration of malignant cells 
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(298). Similarly, protease inhibitors have been reported to be capable 
of inhibiting the growth of tumor cells {299,300}. The documented 
increase of APi in malignant tumors (301) confirmed in this particular 
study could be interpreted as an attempt of the organism to prevent or 
restrain cell proliferation. It has been clearly demonstrated that in 
patients possessing the Z allele serum APi does not increase in response 
to exogenous stimuli, including vaccination (302) and estrogen 
admdnistration (303), factors which normally double the serum 
concentration of APi in subjects with nondeficient phenotypes. It is 
tempting to speculate that in these patients APi deficiency could 
represent a predisposing factor in the initiation of malignant cell 
transformation ana/or in its subsequent proliferation. 
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S~/~ AND CONCLUSION 
In the first chapter, we discussed the different techniques now 
available for precise determination of APi status. ~hasis was placed 
on phenotype determination, using isoelectric focusing and complementary 
print ~unofixation, with special attention to the analysis of the 
latter using mdcrodensitornetry. Several pitfalls encountered during Pi 
determination were discussed, as well as methods to overcome them. 
Finally, a step-by-step procedure for precise deterrodnation of APi 
status was outlined. 
The second chapter was concerned with the study of the different 
molecular variants of APi that represent the Pi system. Several new 
variants -- Mb, Me, and I2 -- were described, and two original 
investigations on the distribution of Pi types in more than 3000 
individuals were reported. A correlation was drawn between the 
expression of the different phenotypes and alleles and the resulting 
serum APi values. Finally, the ~rtance of the Pi system as a genetic 
marker was emphasized. 
The third chapter was devoted to the study of the structure and 
biological role of APi. Following a review of the present state of 
knowledge of the structure of the APi molecule, including recent 
evidence for amino acid substitutions responsible for APi polymorphism, 
we presented personal studies on the role of sialic acid in APi 
isoelectric heterogeneity and polymo~hism. After a brief review of the 
biological role of APi as a protease inhibitor, we reported a study of 
the binding of APi with elastase and t~sin. The results suggest that 
in excess of enzyme the complex between APi and protease is attacked, 
and that as a result the inhibitory effect of APi is completely 
suppressed. 
The fourth chapter dealt with the clinical relevance of APi 
deficiency. TWo main types of disorders are known to be associated with 
this deficien~, i.e., pulmonary and liver involvement. we reported 
personal results describing the predisposing role of APi deficien~ in 
nonatopic infantile asthma, in hemachromatosis, in squamous cell 
carcinoma of the lung, and in rheumatoid arthritis. Prelirndnary data 
concerning an association between deficient Pi phenotypes and 
periodontal disease are also suggestive. All the data seem to indicate 
that the clinical area in which APi deficien~ is ~plicated is much 
wider than previously recognized. This fully justifies the objectives 
of the study. 
Several points need further investigation in association with APi 
studies. ~be most intriguing is the basis for the microheterogeneity 
and polymorphism of this protein, which will be solved only by 
structural studies on the different components of each allele product. 
Our preliminary results concerning APi-protease complexes are also 
particularly intriguing, and could explain the "hit-or-miss" 
consequences of APi deficiency. The precise determination of the 
effects of structural differences in APi molecules on the inactivation 
of several proteolytic enzymes of biological importance remains to be 
studied. 
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The discovery of several new disease states in which APi deficiency 
seems to be strongly involved enhances further the interest of Pi 
determination. It indicates the importance of systematic studies in 
other classes of diseases in which a deficiency of this protein could 
play an ~portant role as a predisposing factor. 
In conclusion, the field of interest of APi covers several domains, 
including fundamental biochemistry, genetics, and clinical research, and 
many important studies remain to be carried out in each of these areas. 
